Histoincompatible skin and marrow grafts in XXXX on @entity205 .

@entity236 @entity205 @entity2132 @entity95
@entity205 (Cy A; 15 mg/kg s.c.) allows allogeneic histoincompatible skin graft survival in 10 of 10 @entity95 as long as the drug is given. The same dose of Cy A does not affect acute @entity2132 ( @entity2132 ) and increase survival of @entity95 after allogeneic bone marrow transplantation between the same two strains, when two groups of 15 animals are tested. Median survival of 14 engrafted animals without Cy A was 23 days, of 12 engrafted animals with Cy A 22 days (not significant). Cryopreservation of bone @entity236 the onset of @entity2132 and increases survival of engrafted animals. Median survival of 5 engrafted animals without Cy A was 33 days, of 14 engrafted animals with Cy A 35 days. Our hypothesis is that one part of early @entity2132 as well as of early graft rejection is mediated by a subclass of cells which is resistant to Cy A. This hypothesis is supported by the finding that most transplanted skins show a self-limited period of infiltration and induration. Skin grafts survive this period of infiltration. If the same potentially self-limited process occurs in the liver or the intestine during acute @entity2132 , animals die. this hypothesis could explain why Cy A allows skin graft survival but does not affect acute @entity2132 .
